Compare BTMD & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | ANVS |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 69.1M |
| IPO Year | 2021 | 2019 |
| Metric | BTMD | ANVS |
|---|---|---|
| Price | $2.00 | $1.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.83 | ★ $13.50 |
| AVG Volume (30 Days) | 216.3K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | 39.39 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $192,219,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $33.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $1.54 |
| 52 Week High | $4.75 | $5.50 |
| Indicator | BTMD | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 41.86 |
| Support Level | $1.97 | $1.79 |
| Resistance Level | $2.17 | $2.38 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 37.58 | 18.32 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.